Filter posts

A Big Year for Novel Drugs Approvals

What was your top Biopharma highlight for 2012? If it wasn’t the stellar move in …

Harder, Better, Faster, Stronger: Takeaways from Partnering For Cures 2012

The chorus to Kanye West’s 2007 chart-topper Stronger can teach us volumes about speeding drug …

Small Companies, Big Returns

The broader biotech indices are up more than 30 percent this year and have reached …

Big Ventures

It is rare to see triple digit millions in private financing rounds, but it does …

The Good, the Bad, and the Ugly for Biotech IPOs

The troubles in the biotech IPO market are complicated to explain to industry outsiders. They …

Choose Your Own Adventure – The Private Biotech Crossroads

It is a known fact within the private company biopharma universe that the days of …

Kinase Drug Development - Making Progress

The kinase inhibition field has had plenty of ups and downs and over the last …

BIO Investor Forum: The New Kids on the Biotech Block

Where should biotech start-ups look for funding in the venture capital desert that is becoming …

How does the NBI perform in the last quarter of the year?

Does the NASDAQ Biotech Index (NBI) outperform the broader market in the last three months …

Is the early-stage IPO making a comeback?

Yesterday was the NASDAQ debut for preclinical-stage biotech Regulus (RGLS). The microRNA platform company is …